Canadian Patent Grant Strengthens Small Pharma’s International Position Post published:August 4, 2022 Post category:Press Release
U.S. Patent Grant to Strengthen Small Pharma’s DMT Patent Strategy With Injectable Formulation Post published:July 27, 2022 Post category:Press Release
George Tziras to Succeed Peter Rands as Small Pharma Chief Executive Officer Post published:July 18, 2022 Post category:Press Release
Small Pharma Reports Fiscal First Quarter 2023 Highlights Post published:July 17, 2022 Post category:Press Release
Small Pharma to Participate in the H.C. Wainwright 1st Annual Mental Health Conference on June 27, 2022 Post published:June 22, 2022 Post category:Press Release
Small Pharma Reports Highlights for the Fiscal Year Ended February 28, 2022 Post published:June 9, 2022 Post category:Press Release
Small Pharma Expands Potential of Commercial Portfolio With DMT-Based Psychedelic Assets Post published:March 10, 2022 Post category:Press Release
World’s First Clinical Trial for DMT-Assisted Therapy in Major Depressive Disorder Shows Consistent Quality of Psychedelic Response in Phase I Post published:February 22, 2022 Post category:Press Release
Small Pharma Reports Fiscal Third Quarter 2021 Highlights Post published:January 31, 2022 Post category:Press Release
Small Pharma Strengthens Board With Appointment of Paul Maier as Independent Director Post published:November 18, 2021 Post category:Press Release